CRDF — Cardiff Oncology, Inc.

Summary of Cardiff Oncology Q4 2024 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2024, Cardiff Oncology reported cash and short-term investments totaling $91.7 million, bolstered by a $40 million capital raise completed in December.
• Operating Cash Burn: The company recorded a cash burn of $10.3 million for Q4 2024, consistent with previous quarters.
• Runway: Current cash resources are projected to sustain operations into Q1 2027.

2. Strategic Updates and Business Highlights

• CRDF-004 Trial: Initial data from the ongoing Phase 2 trial in first-line RAS-Mutated Metastatic Colorectal Cancer (mCRC) showed a 64% overall response rate (ORR) for the 30 mg dose of onvansertib, compared to 33% in the control arm. The trial is nearing completion of its 90 evaluable patient enrollment, expected within weeks.
• Intellectual Property: A new patent was issued covering the use of onvansertib in combination with bevacizumab for KRAS-mutated mCRC, with an expiration date of no earlier than 2043.
• Breast Cancer Research: Two preclinical studies presented at the San Antonio Breast Cancer Symposium demonstrated promising results for onvansertib in combination therapies for hormone receptor-positive breast cancer.

3. Forward Guidance and Outlook

• Cardiff Oncology anticipates releasing additional clinical data from the CRDF-004 trial in the first half of 2025. The company aims to provide a more mature update than the initial 30-patient data.
• The company is in discussions with the FDA regarding dose selection and trial design for a potential registrational trial (CRDF-005).

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The company faces inherent risks associated with clinical trials and regulatory approvals, particularly as they seek to align their strategy with FDA expectations.
• Market Competition: The recent FDA approval of Pfizer's encorafenib for a different patient population may heighten competition in the mCRC space, although Cardiff believes their focus on RAS-mutated patients remains distinct.

5. Notable Q&A Insights

• Data Update Timing: Management indicated that the next data update will focus on providing a more comprehensive view of the trial's outcomes, but PFS data may not be available until later in the year.
• FDA Interaction: Discussions with the FDA will address both dose selection and the design for the registrational trial, with an emphasis on expediting the process.
• Response Rate Comparisons: Management noted that the response rates observed in the BREAKWATER trial align with their findings, reinforcing confidence in their approach.

Overall, Cardiff Oncology is positioned positively with encouraging clinical data and a solid financial foundation, but it must navigate regulatory complexities and competitive pressures in the oncology landscape.